op 2507 has been researched along with thromboxane a2 in 2 studies
| Studies (op 2507) | Trials (op 2507) | Recent Studies (post-2010) (op 2507) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 33 | 0 | 1 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iida, T; Kawarada, Y; Yokoi, H | 1 |
| Arima, T; Hirano, T; Kawano, R; Motoyama, K; Nakafusa, Y; Sugitani, A; Tanaka, M | 1 |
2 other study(ies) available for op 2507 and thromboxane a2
| Article | Year |
|---|---|
The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Disease Models, Animal; Epoprostenol; Injections, Subcutaneous; Kidney; Lung; Male; Methacrylates; Pancreas; Pancreatitis, Acute Necrotizing; Phospholipases A; Phospholipases A2; Rats; Rats, Wistar; Survival Rate; Taurocholic Acid; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase; Time Factors | 1998 |
The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Cell Nucleus; Drug Therapy, Combination; Enzyme Inhibitors; Epoprostenol; Kinetics; Male; Methacrylates; Rats; Rats, Inbred Lew; Rats, Wistar; Superoxides; Thromboxane A2; Thromboxane-A Synthase; Transplantation, Homologous | 2001 |